Form 4: Telomir Pharmaceuticals Director Option Repricing
Statement of Changes in Beneficial Ownership
Director Matthew Pratt Whalen cancelled existing stock options in exchange for new options with a lower exercise price.
Summary
- Director Matthew Pratt Whalen executed a transaction on May 21, 2026, involving the cancellation of 25,000 incentive stock options.
- The cancelled options, originally granted on August 27, 2024, had an exercise price of $5.02.
- In exchange, the director was granted 25,000 new incentive stock options with an exercise price of $1.30.
- The new options are fully exercisable and expire on May 21, 2036.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as neutral to slightly negative, as it indicates the director's previous equity holdings were significantly underwater, reflecting poor stock performance since the 2024 grant.
Positives
- The director maintains alignment with shareholder interests through continued equity participation.
Negatives
- The repricing of options suggests the previous grant was significantly underwater, reflecting a decline in the company's share price since August 2024.
Risks
- Potential dilution of existing shareholders if options are exercised.
- Reflects downward pressure on the company's stock price relative to the 2024 valuation.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the adjustment of director equity compensation.
Management Comments
- The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.
Industry Context
StockSavvy.ai notes that option repricing is a common mechanism in the biotechnology sector to retain key personnel when share prices experience significant volatility or decline, though it can sometimes signal internal concerns regarding valuation recovery.
Comparison to Industry Standards
- Option repricing is a standard corporate governance practice in high-growth biotech firms to maintain incentive alignment during market downturns.
- The practice is generally viewed with scrutiny by institutional investors if it occurs frequently without clear performance-based justification.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation Adjustment | Repricing of director stock options from $5.02 to $1.30. | 05/21/2026 | Maintains director incentive alignment but highlights significant decline in share price. |
Stakeholder Impact
- Shareholders may view the repricing as a signal of management's concern regarding the current stock price valuation.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 08/27/2024 | Original grant date of the cancelled stock options. |
| 05/21/2026 | Date of option cancellation and new grant issuance. |
| 05/22/2026 | Date of filing signature. |
| 05/21/2036 | Expiration date of the new stock options. |
Keywords
Telomir Pharmaceuticals, TELO, Form 4, Stock Options, Director Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.